

## Invitation to Presentation of Promore Pharma's Year-end report for 2018

***STOCKHOLM, 20 February 2019 – Promore Pharma AB (publ) publishes its Year-end report for 2018 at 09.00 CET on 26 February 2019.***

The same day, the company will host a webcast telephone conference at 14.00 CET, with President and CEO Jonas Ekblom and CFO Jenni Björnulfson. After the presentation there will be a Q&A session. The presentation will be held in English. The conference can be accessed via computer, tablet or telephone.

To join the web conference, please use the following link:

<https://global.gotomeeting.com/join/402504493>

To join the telephone conference, please use one of the following numbers:

Sweden: +46 853 527 836

Denmark: +45 32 72 03 82

Finland: +358 923 17 0568

Norway: +47 21 93 37 51

Spain: +34 932 75 2004

UK: +44 20 3713 5028

Germany: +49 691 7489 928

Use the access code 402-504-493 to join the meeting.

The telephone conference and the presentation material will be available on the company's website after the call; [www.promorepharma.com](http://www.promorepharma.com).

### **For additional information, please contact**

Jonas Ekblom, VD

Tel: [+46] 736 777 540

E-mail: [jonas.ekblom@promorepharma.com](mailto:jonas.ekblom@promorepharma.com)

Jenni Björnulfson, CFO

Tel: [+46] 708 55 38 05

E-mail: [jenni.bjornulfson@promorepharma.com](mailto:jenni.bjornulfson@promorepharma.com)

### **Promore Pharma in brief**

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma's two projects are in late stage clinical

development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 has initiated a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North.

*Promore Pharma's Certified Adviser is Redeye AB.*

Phone: [+46] 8 121 576 90

E-mail: [Certifiedadviser@redeye.se](mailto:Certifiedadviser@redeye.se)